These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33730652)

  • 41. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
    Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
    Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
    ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
    Majem M; Cobo M; Isla D; Marquez-Medina D; Rodriguez-Abreu D; Casal-Rubio J; Bueno TM; Bernabé-Caro R; Parente DP; Ruiz-Gracia P; Arroyo MM; Paz-Ares L
    J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33810441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
    Chao J; Fuchs CS; Shitara K; Tabernero J; Muro K; Van Cutsem E; Bang YJ; De Vita F; Landers G; Yen CJ; Chau I; Elme A; Lee J; Özgüroglu M; Catenacci D; Yoon HH; Chen E; Adelberg D; Shih CS; Shah S; Bhagia P; Wainberg ZA
    JAMA Oncol; 2021 Jun; 7(6):895-902. PubMed ID: 33792646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.
    Sonpavde GP; Grivas P; Lin Y; Hennessy D; Hunt JD
    Future Oncol; 2021 Jul; 17(19):2545-2558. PubMed ID: 33783228
    [No Abstract]   [Full Text] [Related]  

  • 46. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
    Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.
    Cramer-van der Welle CM; Verschueren MV; Tonn M; Peters BJM; Schramel FMNH; Klungel OH; Groen HJM; van de Garde EMW;
    Sci Rep; 2021 Mar; 11(1):6306. PubMed ID: 33737641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.
    Matsubara T; Seto T; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Okamoto T
    Onco Targets Ther; 2021; 14():1961-1968. PubMed ID: 33762828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
    Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.
    Umehara K; Yama K; Goto K; Wakamoto A; Hatsuyama T; Honjo O; Saikai T; Fujita A; Sato H
    Cancer Control; 2021; 28():1073274820985790. PubMed ID: 33733906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis.
    Mencoboni M; Ceppi M; Bruzzone M; Taveggia P; Cavo A; Scordamaglia F; Gualco M; Filiberti RA
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy.
    Di Federico A; De Giglio A; Parisi C; Gelsomino F; Ardizzoni A
    Crit Rev Oncol Hematol; 2021 Apr; 160():103302. PubMed ID: 33753247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
    Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
    Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Nishiyama T; Chen LT; Kang YK
    Gastric Cancer; 2021 Jul; 24(4):946-958. PubMed ID: 33743112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL).
    Kagimoto A; Tsutani Y; Mimae T; Miyata Y; Ikeda N; Ito H; Maniwa Y; Suzuki K; Tsuboi M; Yoshimura K; Umemoto S; Okada M
    BMJ Open; 2021 Mar; 11(3):e043234. PubMed ID: 33737428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Yadav A; Malik PS; Khurana S; Jain D; Vishnubhatla S; Yadav M; Pathy S; Mohan A; Kumar L
    Oncology; 2021; 99(6):389-396. PubMed ID: 33735884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
    Halmos B; Burke T; Kalyvas C; Vandormael K; Frederickson A; Piperdi B
    Lung Cancer; 2021 May; 155():175-182. PubMed ID: 33839603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.